[Skip to Content]
[Skip to Content Landing]
August 1997

Adjunctive Use of Mitomycin in Filtration SurgeryIs It Worth the Risk?

Author Affiliations

Baltimore, Md

Arch Ophthalmol. 1997;115(8):1068-1069. doi:10.1001/archopht.1997.01100160238015

The title of this editorial may be questioned by some surgeons given the current widespread use of antimetabolites in filtration surgery. However, consider the evolution of filtration surgery during the last 10 years. Within a short period, the techniques of filtration surgery have changed dramatically, more markedly than during the previous 25 years. During my fellowship in the mid-1980s, full-thickness filtration surgery was touted as the desired procedure for achieving low intraocular pressures in high-risk eyes.1 By the late 1980s, the Fluorouracil Filtering Surgery Study,2 which was supported by the National Eye Institute, National Institutes of Health, Bethesda, Md, reassured clinicians that antimetabolites could be safely used in glaucomatous eyes and it was not much longer before we were giving fluorouracil injections to patients undergoing primary filtration surgery. In 1990, Palmer3 introduced North America to mitomycin, a potent antimetabolite that inhibits fibroblastic proliferation in vitro for more

First Page Preview View Large
First page PDF preview
First page PDF preview